Truist lowered the firm’s price target on Cigna (CI) to $310 from $375 and keeps a Buy rating on the shares after its Q3 results and outlook. PBM – Pharmacy Benefit Services – was the main area of focus as proactive, sizable client re-contracting and investments to support the new rebate-free model are expected to weigh on FY26 margins, while Specialty and Healthcare are expected to grow at the high-end of their respective long-term targets, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Cigna’s Earnings Call: Strong Performance Amid Challenges
- Cigna price target lowered to $355 from $390 at Morgan Stanley
- Cigna price target lowered to $300 from $383 at Barclays
- Cigna’s Strategic Initiatives Poised for Long-Term Growth Despite Short-Term Challenges
- Cigna Group Reports Strong Q3 2025 Results